Cargando…

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022

Detalles Bibliográficos
Autores principales:	Hause, Anne M., Baggs, James, Marquez, Paige, Abara, Winston E., Baumblatt, Jane Gwira, Thompson, Deborah, Su, John R., Myers, Tanya R., Gee, Julianne, Shimabukuro, Tom T., Shay, David K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2022
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290389/ https://www.ncbi.nlm.nih.gov/pubmed/35834416 http://dx.doi.org/10.15585/mmwr.mm7128a3

Ejemplares similares

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022
por: Woo, Emily Jane, et al.
Publicado: (2023)

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study
por: Wong, Karen K, et al.
Publicado: (2022)

January 2022-December 2022
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine Among Persons Aged ≥12 Years — United States, July 13, 2022–March 13, 2023
por: Romanson, Brittney, et al.
Publicado: (2023)

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults
por: Tompkins, Lindsay K., et al.
Publicado: (2022)

Investigation into cases of hepatitis of unknown aetiology among young children, Scotland, 1 January 2022 to 12 April 2022
por: Marsh, Kimberly, et al.
Publicado: (2022)

COVID-19 Booster Vaccination in the U.S. Military, August 2021–January 2022
por: Winkler, Erin L., et al.
Publicado: (2023)

Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States
por: Abara, Winston E., et al.
Publicado: (2023)

Projection of healthcare demand in Germany and Switzerland urged by Omicron wave (January–March 2022)
por: Gorji, Hossein, et al.
Publicado: (2023)

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
por: Smith, Dallas J., et al.
Publicado: (2022)

COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
por: Smith, Dallas J., et al.
Publicado: (2022)

Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months–5 Years — United States, June 17, 2022–May 7, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

INTERNATIONAL NEWS - March 2022
Publicado: (2022)

Editors’ page‐March 2022
por: Michos, Erin D., et al.
Publicado: (2022)

Staff Council of January 18, 2022
por: Staff Association
Publicado: (2022)

Salary Scale 1 January 2022
por: Stappers, Sara
Publicado: (2022)

PRAC meeting highlights January 2022
Publicado: (2022)

COVID-19 Booster Dose Vaccination Coverage and Factors Associated with Booster Vaccination among Adults, United States, March 2022
por: Lu, Peng-jun, et al.
Publicado: (2023)

Epidemiological Comparison of Four COVID-19 Waves in the Democratic Republic of the Congo, March 2020–January 2022
por: Otshudiema, John Otokoye, et al.
Publicado: (2022)

Use of At-Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022
por: Rader, Benjamin, et al.
Publicado: (2022)

SUSY Summary Plots March 2022
por: The ATLAS collaboration
Publicado: (2022)

Epilepsia Open—March 2022—Announcements
Publicado: (2022)

PRAC meeting highlights March 2022
Publicado: (2022)

Periodic Actuarial Review as at 1 January 2022
Publicado: (2022)

Human vaccines & immunotherapeutics news: January 2022
Publicado: (2022)

Volume 104, Issue 1, January 2022
por: Valavanis, Kimon P.
Publicado: (2022)

CERN Bulletin Issue No. 10-12/2022
Publicado: (2022)

CERN Bulletin Issue No. 12-13/2022
Publicado: (2022)

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
por: Rosenblum, Hannah G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ua8et9ljcn76sfl87nc5eujtf